JP5818693B2 - インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体 - Google Patents

インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体 Download PDF

Info

Publication number
JP5818693B2
JP5818693B2 JP2011550155A JP2011550155A JP5818693B2 JP 5818693 B2 JP5818693 B2 JP 5818693B2 JP 2011550155 A JP2011550155 A JP 2011550155A JP 2011550155 A JP2011550155 A JP 2011550155A JP 5818693 B2 JP5818693 B2 JP 5818693B2
Authority
JP
Japan
Prior art keywords
seq
residues
virus
polypeptide
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011550155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517239A (ja
JP2012517239A5 (cg-RX-API-DMAC7.html
Inventor
ジン，ホン
チェン，シン
スバラオ，カンタ
Original Assignee
メディミューン，エルエルシー
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ ナショナル インスティテューツ オブ ヘルス
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ ナショナル インスティテューツ オブ ヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー, ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ ナショナル インスティテューツ オブ ヘルス, ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ ナショナル インスティテューツ オブ ヘルス filed Critical メディミューン，エルエルシー
Publication of JP2012517239A publication Critical patent/JP2012517239A/ja
Publication of JP2012517239A5 publication Critical patent/JP2012517239A5/ja
Application granted granted Critical
Publication of JP5818693B2 publication Critical patent/JP5818693B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011550155A 2009-02-12 2010-02-03 インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体 Expired - Fee Related JP5818693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15209409P 2009-02-12 2009-02-12
US61/152,094 2009-02-12
PCT/US2010/022970 WO2010093537A2 (en) 2009-02-12 2010-02-03 Influenza hemagglutinin and neuraminidase variants

Publications (3)

Publication Number Publication Date
JP2012517239A JP2012517239A (ja) 2012-08-02
JP2012517239A5 JP2012517239A5 (cg-RX-API-DMAC7.html) 2013-03-14
JP5818693B2 true JP5818693B2 (ja) 2015-11-18

Family

ID=42562246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011550155A Expired - Fee Related JP5818693B2 (ja) 2009-02-12 2010-02-03 インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体

Country Status (11)

Country Link
US (2) US8613935B2 (cg-RX-API-DMAC7.html)
EP (1) EP2396033B1 (cg-RX-API-DMAC7.html)
JP (1) JP5818693B2 (cg-RX-API-DMAC7.html)
CN (1) CN102361649A (cg-RX-API-DMAC7.html)
AU (1) AU2010213966B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1008549A2 (cg-RX-API-DMAC7.html)
CA (1) CA2752205A1 (cg-RX-API-DMAC7.html)
MX (2) MX2011008497A (cg-RX-API-DMAC7.html)
RU (2) RU2535970C2 (cg-RX-API-DMAC7.html)
SG (2) SG2014010185A (cg-RX-API-DMAC7.html)
WO (1) WO2010093537A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0610525Y2 (ja) 1986-02-06 1994-03-16 三洋電機株式会社 キヤプスタンモ−タ制御回路

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568015C (en) 2004-05-25 2013-08-27 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2008021959A2 (en) 2006-08-09 2008-02-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
CA2752205A1 (en) 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2012040406A2 (en) * 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
CN108103084B (zh) * 2017-11-21 2020-06-26 浙江迪福润丝生物科技有限公司 区分免疫和感染动物h5亚型禽流感疫苗株及其制备方法和应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992522A (en) * 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US4071618A (en) * 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
ATE302277T1 (de) 1992-04-14 2005-09-15 Sinai School Medicine Gentechnologisch abgeschwächte virus
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
DK0702085T4 (da) * 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5690937A (en) * 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
AU727923B2 (en) 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
KR100552387B1 (ko) 1995-10-31 2006-04-21 가부시끼가이샤 디나벡 겡뀨쇼 자율 복제 능력을 갖는 (-)쇄 rna 바이러스 벡터
DK0863202T3 (da) 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
US6090391A (en) * 1996-02-23 2000-07-18 Aviron Recombinant tryptophan mutants of influenza
JP4413999B2 (ja) 1996-07-15 2010-02-10 アメリカ合衆国 クローニングされたヌクレオチド配列からの弱毒化呼吸シンシチウムウィルスワクチンの製造
KR20000048628A (ko) 1996-09-27 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이
KR100702523B1 (ko) 1997-05-23 2007-04-04 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법
EP1012244B1 (en) 1997-07-11 2007-05-09 Yale University Rhabdoviruses with reengineered coats
WO1999015672A1 (en) 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
EP1035209A1 (en) 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
IL145702A0 (en) 1999-04-06 2002-07-25 Wisconsin Alumni Res Found Recombination influenza viruses for vaccines and gene theraphy
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
DE60112050T2 (de) 2000-03-02 2006-04-27 Polymun Scientific Immunbiologische Forschung Gmbh Rekombinantes influenza a virus
SI1317559T1 (sl) * 2000-04-28 2009-04-30 St Jude Childrens Res Hospital Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna
CN1582333B (zh) * 2000-09-25 2010-06-16 波利门科学生物免疫研究有限公司 活疫苗及生产方法
USPP15035P3 (en) * 2001-06-27 2004-07-27 Marko Zaninovich, Inc. Grapevine ‘12-76-71’
KR100600988B1 (ko) * 2002-03-13 2006-07-13 주식회사 엘지생명과학 Ｄｎａ 면역화에서 인플루엔자 ｎｐ 유전자 ｄｎａ를 함께투여하여 면역반응을 증가시키는 방법
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
ES2526191T3 (es) 2002-04-26 2015-01-08 Medimmune, Llc Método para producir virus influenza B infeccioso en cultivo celular
CA2529647C (en) * 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
CA2568015C (en) * 2004-05-25 2013-08-27 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2388340B1 (en) 2004-11-01 2013-04-03 Eiken Kagaku Kabushiki Kaisha Method of detecting H7 avian influenza virus
EP2441471B1 (en) * 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
RU2315101C2 (ru) * 2006-01-10 2008-01-20 ГУ "Научно-исследовательский институт экспериментальной медицины "Российской Академии медицинских наук (ГУ НИИЭМ РАМН) Вакцинный штамм вируса гриппа а/17/калифорния/ 04/6 (н3n2) и донор аттенуации а/ленинград/134/17/к7/57 (н2n2) для его получения
WO2008021959A2 (en) * 2006-08-09 2008-02-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2009014919A2 (en) * 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use
CA2752205A1 (en) 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0610525Y2 (ja) 1986-02-06 1994-03-16 三洋電機株式会社 キヤプスタンモ−タ制御回路

Also Published As

Publication number Publication date
JP2012517239A (ja) 2012-08-02
EP2396033B1 (en) 2016-09-28
SG173642A1 (en) 2011-09-29
RU2535970C2 (ru) 2014-12-20
CA2752205A1 (en) 2010-08-19
US20140079726A1 (en) 2014-03-20
BRPI1008549A2 (pt) 2016-03-15
US8613935B2 (en) 2013-12-24
AU2010213966B2 (en) 2015-01-22
US20100330118A1 (en) 2010-12-30
WO2010093537A2 (en) 2010-08-19
CN102361649A (zh) 2012-02-22
MX2011008497A (es) 2011-12-16
AU2010213966A1 (en) 2011-09-01
US9119812B2 (en) 2015-09-01
EP2396033A2 (en) 2011-12-21
EP2396033A4 (en) 2013-10-23
MX343411B (es) 2016-11-04
SG2014010185A (en) 2014-06-27
RU2014140731A (ru) 2016-04-27
WO2010093537A3 (en) 2010-10-07
RU2011137404A (ru) 2013-03-20

Similar Documents

Publication Publication Date Title
JP4980895B2 (ja) インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
JP5745550B2 (ja) インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
US8333975B2 (en) Influenza hemagglutinin and neuraminidase variants
US8685410B2 (en) Influenza hemagglutinin and neuraminidase variants
JP2011527581A (ja) インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
US9119812B2 (en) Influenza hemagglutinin and neuraminidase variants
HK1166277A (en) Influenza hemagglutinin and neuraminidase variants
HK1184060A (en) Influenza hemagglutinin and neuraminidase variants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130122

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20140217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150703

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150714

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150929

R150 Certificate of patent or registration of utility model

Ref document number: 5818693

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees